Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with FC vs FC alone in Relapsed CLL
NCT00090051Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2003
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of rituximab in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Roche. Primary endpoints: Progression-free Survival at 26 months and Number of Participants With Progression-free Survival Events at 26 months. Started Jul 2003; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00090051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090051.